Optis
Payments companies reported to CMS as associated with Optis. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Optis, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Optis
These are the largest totals companies reported as associated with Optis. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Kevin Croce | Chestnut Hill, MA | Cardiovascular Disease | $306,292.75 |
| Jason Wollmuth | Portland, OR | Interventional Cardiology | $192,357.74 |
| Duane Pinto | Boston, MA | Interventional Cardiology | $126,694.62 |
| Emmanouil Brilakis | Minneapolis, MN | Interventional Cardiology | $98,932.69 |
| Brian Bergmark | Boston, MA | Cardiovascular Disease | $95,995.97 |
| Megha Prasad | New York, NY | Cardiovascular Disease | $88,530.31 |
| Kathleen Kearney | Seattle, WA | Interventional Cardiology | $78,027.37 |
| Ethan Korngold | Portland, OR | Interventional Cardiology | $77,122.05 |
| Ziad Ali | New York, NY | Internal Medicine | $73,925.21 |
| Hayder Hashim | Washington, DC | Cardiovascular Disease | $73,372.86 |
Prescribed Optis?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.